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Apart	from	potential	roles	in	anti-tumor	surveillance,	the	TNF-related	apoptosis-inducing	ligand	(TRAIL)	has	
important	regulatory	functions	in	the	host	immune	response.	We	studied	antiinflammatory	effects	of	endog-
enous	and	recombinant	TRAIL	(rTRAIL)	in	experimental	meningitis.	Following	intrathecal	application	of	
pneumococcal	cell	wall,	a	TLR2	ligand,	we	found	prolonged	inflammation,	augmented	clinical	impairment,	
and	increased	apoptosis	in	the	hippocampus	of	TRAIL–/–	mice.	Administration	of	rTRAIL	into	the	subarach-
noid	space	of	TRAIL–/–	mice	or	reconstitution	of	hematopoiesis	with	wild-type	bone	marrow	cells	reversed	these	
effects,	suggesting	an	autoregulatory	role	of	TRAIL	within	the	infiltrating	leukocyte	population.	Importantly,	
intrathecal	application	of	rTRAIL	in	wild-type	mice	with	meningitis	also	decreased	inflammation	and	apopto-
sis.	Moreover,	patients	suffering	from	bacterial	meningitis	showed	increased	intrathecal	synthesis	of	TRAIL.	
Our	findings	provide	what	we	believe	is	the	first	evidence	that	TRAIL	may	act	as	a	negative	regulator	of	acute	
CNS	inflammation.	The	ability	of	TRAIL	to	modify	inflammatory	responses	and	to	reduce	neuronal	cell	death	
in	meningitis	suggests	that	it	may	be	used	as	a	novel	antiinflammatory	agent	in	invasive	infections.
Introduction
Previous research on TNF-related apoptosis-inducing ligand 
(TRAIL; also termed APO2L) has mostly focused on its ability to 
induce apoptosis in transformed cells but not in most normal 
cells. TRAIL is a potential antitumor therapy (1). In addition, 
there is a growing understanding of the physiological functions 
of endogenous TRAIL in immunity. TRAIL death receptors and 
decoy receptors are present on peripheral blood leukocytes (2–6) 
and may play an important role in antitumor surveillance by the 
immune system (7) and in the regulation of cell survival.
Inhibitory effects of TRAIL on (auto)antigen-specific T lympho-
cytes or thymocytes were demonstrated not only in vitro (8) but 
also in vivo in models such as experimental autoimmune encepha-
lomyelitis (9) and autoimmune arthritis (10, 11). Accordingly, sol-
uble TRAIL (sTRAIL) levels were upregulated in multiple sclerosis 
patients treated with immune-regulatory interferon β therapy and 
highest in patients responding to this therapy (12). Recently, the 
TRAIL system has been implicated in the elimination of senescent 
circulating neutrophils (4, 13) as well as in the clearance of acti-
vated tissue neutrophils (14).
Leukocytes are the first line of defense in acute bacterial infec-
tions but have also been identified as key effectors of damage in 
bacterial meningitis (15–17). Acute bacterial meningitis is still a 
life-threatening invasive infectious disease. Despite effective anti-
biotic treatment, mortality remains as high as 30%, and only half 
of the survivors return to work (18, 19). Clinical complications, 
such as the formation of brain edema, increased intracranial pres-
sure, and alterations of the cerebral blood flow, contribute to 
the unfavorable outcome. These alterations are largely mediated 
by host immune responses and leukocyte function (15, 20, 21). 
Additionally, there is a substantial risk of long-term neuropsycho-
logical sequelae in survivors (22, 23). Such impairment has been 
linked to neuronal loss, mostly by apoptosis, which is particularly 
pronounced in the hippocampus (24–27). Experimental data in 
meningitis caused by Streptococcus pneumoniae — the most frequent 
and disastrous pathogen in meningitis — suggest that bacterial 
toxins, such as the pore-forming pneumolysin or hydrogen perox-
ide, mediate approximately 50% of the neuronal cell loss while the 
remaining neuronal damage is driven by host immune responses 
(25–27). In the context of antibiotic therapy, it is highly desirable 
to limit the inflammatory process in order to prevent such acute 
and chronic complications (28).
Today, evidence-based adjunctive treatment of meningitis is lim-
ited to dexamethasone (19, 29). In pneumococcal meningitis in 
particular, mortality and frequency of complications are reduced 
by this treatment (29), but important issues surround the question 
of whether glucocorticoids impair the penetration of antibiotics 
into the cerebrospinal fluid (CSF) (30, 31) or worsen the neuronal 
damage (32). Specifically, neutrophil survival is prolonged by glu-
cocorticoids (33, 34); this raises the risk of cytotoxic effects.
In the present study, we found elevated levels of sTRAIL in the 
CSF of patients with bacterial meningitis. We hypothesized that 
the TRAIL system is an essential regulator of leukocyte survival in 
the CSF during meningitis and that recombinant TRAIL (rTRAIL) 
could be used to modulate the inflammatory response in invasive 
infections, such as bacterial meningitis.
Results
sTRAIL is elevated in the CSF of patients with bacterial meningitis. The 
concentration of sTRAIL in the CSF (Figure 1A) and the CSF to 
serum ratio (Figure 1B) were significantly increased in patients 
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diagnosed with bacterial meningitis compared with control 
patients. The level of sTRAIL correlated significantly with the 
leukocyte count in the CSF (Figure 1C). These data indicate that 
sTRAIL is released into the CSF compartment, suggesting a spe-
cific role for TRAIL in bacterial meningitis.
Effect of TRAIL genotype on the influx of leukocytes in 
experimental meningitis. Intrathecal application of 
pneumococcal cell wall (PCW), an established model 
of experimental meningitis in mice (35), caused 
a pronounced influx of leukocytes into the CSF 
(n = 5 to 10 animals/genotype and time point). In 
wild-type mice, pleocytosis was highest at 12 hours 
and resolved almost completely within 24 hours 
after meningitis induction (Figure 2A). In TRAIL–/– 
mice, we observed a delayed and protracted influx of 
leukocytes, with the highest concentration present 
at 18 hours and persistence at 48 hours. While the 
TRAIL genotype had no significant impact on the 
differential hemograms of untreated mice (Supple-
mental Figure 1A; supplemental material available 
online with this article; doi:10.1172/JCI30356DS1), 
we observed a substantial effect on the kinetics of 
leukocyte subsets in the CSF after meningitis induc-
tion (Figure 2B): in wild-type mice, an initial gran-
ulocytic phase was followed by rapid clearance of 
granulocytes and a predominance of mononuclear 
cells. In comparison, granulocytes were much less 
abundant in the CSF of TRAIL–/– mice during early 
meningitis, and their percentage did not decrease 
during the experimental period. At 12 hours, the dif-
ference in the absolute number of granulocytes (on 
average, 10,450/μl in wild-type mice versus 1,640/μl 
in TRAIL–/– mice; difference: 8,810/μl) determined 
the difference in the total number of CSF leukocytes 
(on average, 12,440 leukocytes/μl in wild-type mice 
versus 5,656 leukocytes/μl in TRAIL–/– mice; differ-
ence: 6,784/μl). These data suggest important effects 
of TRAIL on CSF leukocyte kinetics in meningitis.
We performed immunostainings of brain sections 
to determine whether the degree of tissue infiltra-
tion by granulocytes was also modulated by the 
TRAIL genotype. In general, few myeloperoxidase-
immunoreactive (MPO-immunoreactive) cells were identified 
in the brain, usually with highest abundance in the subcortical 
white matter. At 12 hours after challenge, 5.7 ± 1.0 MPO-positive 
cells/mm2 were found in the brain tissue of wild-type mice com-
pared with 1.9 ± 1.7 cells/mm2 in TRAIL–/– mice (P < 0.05). At 18 
Figure 1
TRAIL is released into the CSF of patients with acute meningitis. (A) In CSF samples from patients with acute bacterial meningitis, the concentra-
tion of sTRAIL is significantly higher than in patients with other noninflammatory diseases (OND). **P < 0.01, Student’s t test. (B) The increased 
CSF/serum ratio supports an intrathecal source of sTRAIL during meningitis. **P < 0.01, Student’s t test. (C) The concentration of TRAIL in CSF 
correlated significantly with the cell count. Spearman’s r = 0.717; P = 0.016.
Figure 2
Leukocyte viability and persistence in the CSF are increased in TRAIL–/– mice. (A) CSF 
leukocyte counts at specified time points following meningitis induction. Compared 
with wild-type C57BL/6 mice, TRAIL–/– mice show delayed influx of leukocytes into the 
CSF and delayed resolution of inflammation. **P < 0.01, Student’s t test. (B) Relative 
proportions of leukocyte subpopulations in the CSF of wild-type and TRAIL–/– mice at 
12, 18, and 24 hours after meningitis induction. Granulocytes (Gran) predominate in 
the early phase of experimental meningitis in wild-type mice while their accumulation 
is delayed in TRAIL–/– mice. Mono, monocytes; Ly, lymphocytes. (C) Proportion of 
nonviable cells of the total CSF leukocyte concentration at 12, 18, and 24 hours after 
meningitis induction in wild-type mice and TRAIL–/– mice as identified by AOEB stain-
ing (see also Supplemental Figure 1). Prolonged survival of activated CSF leukocytes 
is observed in TRAIL–/– mice. P < 0.01 at 18 hours and at 24 hours; Student’s t test. (D) 
Leukocyte apoptosis in pooled CSF samples from TRAIL–/– mice at 12 hours after men-
ingitis induction. One representative experiment out of 2 is shown. rTRAIL (100 ng/ml) 
accelerates leukocyte apoptosis ex vivo. **P < 0.01, log rank test.
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hours, 1.0 ± 0.5 MPO-positive cells/mm2 were present in wild-type 
mice compared with 1.5 ± 1.0 cells/mm2 in TRAIL–/– mice (P = 0.44). 
MPO-immunoreactive cells were extremely rare within the dentate 
gyrus (1 cell in 1 out of 21 animals). Moreover, double staining for 
MPO with the TUNEL reaction did not identify apoptotic brain 
cells in the vicinity of MPO-positive leukocytes. Cells stained for 
both TUNEL and MPO were present in the subarachnoid space 
but not within the brain parenchyma (data not shown).
Effect of TRAIL on leukocyte viability in the CSF. CSF samples were 
examined for the percentage of viable leukocytes using acridine 
orange plus ethidium bromide (AOEB) staining (Figure 2C and 
Supplemental Figure 1; n = 3 to 6 animals/group). At 12 hours 
after meningitis induction, AOEB staining demonstrated viabil-
ity of virtually all leukocytes regardless of the TRAIL genotype. In 
wild-type mice, the vast majority of the leukocytes still present at 
18 hours and 24 hours were dead. In contrast, TRAIL–/– mice had 
significantly more leukocytes in the CSF, 
and most of these cells remained viable 
even at 24 hours after challenge. All find-
ings were supported by TUNEL staining 
(Supplemental Figure 1) and suggest a 
longer survival of invading leukocytes 
in TRAIL–/– mice during meningitis. In 
pooled CSF collected from TRAIL–/– mice 
12 hours after meningitis induction 
(2 independent studies, n = 3 and n = 6), 
addition of 100 ng/ml rTRAIL acceler-
ated leukocyte apoptosis ex vivo as indi-
cated by AOEB staining (log rank test, 
P < 0.01; Figure 2D).
Effect of TRAIL genotype on cytokine 
mRNA expression levels during meningitis.  
We also performed tests to deter-
mine whether TRAIL modulated the 
cytokine balance in the brain in men-
ingitis. Measurements of cytokine lev-
els in the CSF were impossible due to 
the small sample volumes. Real-time 
PCR was performed on cerebellar tis-
sue homogenates and revealed higher 
mRNA expression levels of proinflam-
matory cytokines (Tnfa, Ifng, and CXC 
chemokine ligand 12 [Cxcl12]) and anti-
inflammatory cytokines (Tgfb, Il4, and 
Il10) in TRAIL–/– mice compared with 
wild-type mice at 18 hours and 24 hours 
after intrathecal challenge with PCW 
(P < 0.01 for Tnfa and Tgfb; Table 1). 
No difference was observed for the ratio 
of pro- to antiinf lammatory 
cytokine mRNAs in wild-type 
mice versus TRAIL–/– mice.
Effect of TRAIL genotype on apop-
tosis in the dentate gyrus. Twenty-
four hours after intrathecal 
application of PBS, the baseline 
rate of TUNEL-positive cells in 
the dentate gyrus was slightly 
lower in wild-type mice than in 
TRAIL–/– mice (n = 4/group). 
Meningitis induction in wild-type mice (n = 8) and TRAIL–/– mice 
(n = 8) increased the number of apoptotic cells, and the relative 
increase was markedly higher in TRAIL–/– mice (240% ± 35%) than 
in wild-type mice (156% ± 20%; P < 0.01). The number of apoptotic 
cells in the dentate gyrus depended on the CSF leukocyte concen-
tration more strongly than on the host genotype (Figure 3B).
Effect of TRAIL genotype on clinical impairment during meningitis. As 
a measure of overall coordination and motor strength, we used 
the tightrope test. In this test, all wild-type and TRAIL–/– control 
mice were able to hold on to a horizontally suspended string for at 
least 30 seconds (Figure 3, C and D). Following meningitis induc-
tion, very little or no impairment was observed in wild-type mice 
between 18 hours (Figure 3C) and 24 hours (Figure 3D) whereas 
the majority of TRAIL–/– mice with meningitis were unable to com-
plete the task. These data demonstrate that there is an increased 
acute functional deficit in TRAIL–/– mice with meningitis.
Table 1
Expression of cytokine mRNA levels
	 Tnfa	(10–6)	 Ifng	(10–8)	 Cxcl12	(10–5)	 Tgfb	(10–5)	 Il4	(10–7)	 Il10	(10–8)
C57BL/6 1.13 ± 1.24 2.37 ± 3.74 5.84 ± 5.46 1.61 ± 1.49 ND 1.81 ± 4.06
TRAIL–/– 6.20 ± 3.53A 5.23 ± 9.39 15.40 ± 5.52 5.44 ± 2.40A 1.16 ± 2.37 10.90 ± 7.25
Shown is expression of cytokine mRNA levels in the cerebellum of wild-type C57BL/6 and TRAIL–/– mice at 
18 hours to 24 hours after intrathecal challenge with PCW. Values are expressed relative to GAPDH mRNA 
(means ± SD). ND, not detected. AP < 0.05, Student’s t test.
Figure 3
Apoptosis in the hippocampus and clinical impairment are augmented in TRAIL–/– mice with meningi-
tis. (A) Twenty-four hours after meningitis induction, there is an increase in the number of TUNEL-pos-
itive apoptotic cells/mm2 of the dentate gyrus in TRAIL–/– mice and wild-type mice compared with that 
in PBS-treated controls. *P < 0.05; **P < 0.01, 1-way ANOVA with Student-Neuman-Keuls post hoc 
analysis. Meningitis caused a much stronger increase of apoptotic cell death in TRAIL–/– mice than in 
wild-type mice compared with controls. ##P < 0.01, Student’s t test. Examples of TUNEL-stained cells 
are shown in Supplemental Figure 2. (B) Correlation of the number of TUNEL-positive cells/mm2 
in the dentate gyrus with the concentration of CSF leukocytes at 24 hours after meningitis induction. 
Multiple regression analysis identified the leukocyte count as a stronger predictor of damage than 
the genotype (Tleukocytes = 7.2; Tgenotype = 2.0). (C and D) Motor and coordination assessment with the 
tightrope test at 18 hours (C) and 24 hours (D) after meningitis induction. Clinical impairment is more 
pronounced in TRAIL–/– mice compared with wild-type mice. **P < 0.01, log rank test. All control mice 
were able to hold on to the rope for at least 30 seconds.
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Expression of TRAIL receptor 2 on granulocytes. We assumed a reg-
ulatory role of TRAIL on the apoptosis of activated granulocytes 
in the CSF. Using FACS analysis, we demonstrated the presence 
of the TRAIL death receptor TRAIL receptor 2 (TRAIL-R2) on 
Gr-1-positive peripheral blood leukocytes in untreated wild-
type mice (Figure 4, A–C). Additional staining was performed on 
brain sections from wild-type mice at 12 hours after meningitis 
induction. Here, TRAIL-R2 immunoreactivity was present main-
ly on microglia and on the majority of infiltrating granulocytes 
identified by their MPO expression (Supplemental Figure 3A).
Intrathecal administration of rTRAIL restores leukocyte clearance in the 
CSF. Intrathecal administration of rTRAIL in PBS-challenged ani-
mals did not induce leukocyte influx into the CSF of wild-type 
mice (n = 3) or TRAIL–/– mice (n = 6) at 24 hours after surgery. 
In TRAIL–/– animals with meningitis, we observed a dose-depen-
dent reduction of the number of CSF leukocytes at 24 hours after 
meningitis induction (Figure 4D; n = 4/group). In wild-type mice 
with meningitis, the low CSF cell count at 24 hours was not sig-
nificantly modulated by rTRAIL (n = 4/group). Having determined 
that 1 μg rTRAIL was required for the reduction of CSF leukocyte 
counts, we went on to explore the effects of rTRAIL administration 
at an earlier time point after meningitis induction. Administration 
of 1 μg rTRAIL/animal resulted in a marked decrease in CSF leu-
kocyte counts at 12 hours after meningitis induction (Figure 4E) 
in both TRAIL–/– and wild-type mice (n = 6/group).
rTRAIL reduces apoptosis in the hippocampus after experimental meningitis. 
Next, we determined the effect of rTRAIL on the rate of apoptosis in 
the dentate gyrus at 24 hours after meningitis induction (Figure 4F). 
In TRAIL–/– mice with meningitis, intrathecal administration of 
1 μg rTRAIL led to a marked reduction of TUNEL-positive cells in 
the dentate gyrus. In fact, the levels of TUNEL-positive cells were 
similar to those of wild-type animals with meningitis. Moreover, 
administration of rTRAIL reduced the number of TUNEL-positive 
cells in the dentate gyrus even in wild-type mice with meningitis. 
rTRAIL had no effect on the number of TUNEL-positive cells in 
the dentate gyrus of PBS-challenged animals of either genotype 
(data not shown).
Effects of CD18 inhibition or granulocyte depletion in experimental men-
ingitis. In wild-type mice, parenteral treatment with the blocking 
monoclonal anti-CD18 antibody GAME46 (n = 7) effectively inhib-
ited leukocyte recruitment to the CSF (Figure 4G) and reduced 
the number of TUNEL-positive cells in the dentate gyrus 24 hours 
after meningitis induction compared with those in mice challenged 
with PCW alone (n = 8). Granulocytic depletion of TRAIL–/– mice 
Figure 4
rTRAIL modulates inflammation and apoptosis in the hippocampus of wild-type and TRAIL–/– mice with meningitis. (A–C) FACS analysis of 
murine peripheral blood demonstrates the presence of TRAIL-R2 on Gr-1–positive leukocytes. (A) Gr-1 staining and isotype control staining 
for TRAIL-R2. PE, phycoerthrin. (B) Double staining for Gr-1 and TRAIL-R2. (C) Histogram plot of TRAIL-R2 expression in the gated Gr-1high 
population. Isotype control (gray curve); TRAIL-R2 (black curve). (D–F) Effects of treatment with rTRAIL in experimental meningitis. (D) In 
TRAIL–/– mice, a dose-dependent reduction of pleocytosis was observed 24 hours after intrathecal administration of 0.1–1 μg rTRAIL and PCW. 
In wild-type mice, rTRAIL had no effect. (E) At 12 hours after meningitis induction, coapplication of 1 μg rTRAIL with PCW reduced the levels 
of pleocytosis in wild-type mice and TRAIL–/– mice. (F) rTRAIL reduced apoptosis in the dentate gyrus at 24 hours after meningitis induction 
in wild-type and TRAIL–/– mice. (G) Parenteral administration of an antibody against CD18 significantly reduced the recruitment of leukocytes 
across the blood-brain barrier in wild-type mice. (H) CD18 inhibition also diminished the number of TUNEL-positive cells in the dentate gyrus at 
24 hours after meningitis induction in wild-type mice. (D–H) *P < 0.05; **P < 0.01, Student’s t test or Mann-Whitney U test as appropriate. (I) In 
TRAIL–/– mice, depletion of granulocytes with an antibody against Ly6G reduced the number of TUNEL-positive cells in the dentate gyrus at 24 
hours after meningitis induction. **P < 0.01, Student’s t test. Intrathecal treatment with 1 μg rTRAIL diminished apoptosis in the dentate gyrus of 
nondepleted mice at 24 hours after meningitis induction (P < 0.01, Student’s t test), but no additional effect of rTRAIL was present in granulocyte-
depleted mice. P = NS, 2-way ANOVA. DG, dentate gyrus.
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by pretreatment with a monoclonal anti-Ly6G antibody (Figure 4I) 
reduced apoptosis in the dentate gyrus at 24 hours after PCW 
administration compared with that in nondepleted TRAIL–/– mice 
treated with isotype control antibody. In the nondepleted mice, 
administration of 1 μg rTRAIL significantly reduced the number 
of apoptotic cells in the dentate gyrus after experimental meningi-
tis while no effect of rTRAIL was observed in granulocyte-depleted 
mice with meningitis. These findings confirm the important role of 
leukocytes in the induction of apoptosis in the hippocampus dur-
ing nonreplicative bacterial meningitis. Moreover, they suggest that 
TRAIL is not a primary effector of granulocyte-induced cell death.
Effect of rTRAIL on the activation of murine granulocytes. In order to 
assess potential effects of TRAIL on the activation of granulocytes, 
we studied the regulation of CD18 surface antigen expression using 
FACS analysis of peripheral blood leukocytes from wild-type mice 
(n = 7). Granulocytes were identified by the coexpression of high 
levels of CD11b and Gr-1 antigens (CD11bhigh/Gr-1high). Within 
the CD11bhigh/Gr-1high population, 2 subpopulations of granulo-
cytes with low versus high expression of CD18 antigen were distin-
guishable in all samples (data not shown). The fraction of CD18high 
granulocytes increased from 8.4% ± 4.4% in unstimulated control 
samples to 22.6% ± 1.5% after stimulation with PCW (P < 0.05 ver-
sus control) and to 26.6% ± 0% after stimulation with 1 μM PMA for 
10 minutes (P < 0.05 versus control). We did not observe any signifi-
cant effects of rTRAIL in concentrations between 5 and 50 ng/ml 
on the proportion of CD18high granulocytes (data not shown). At 
higher doses, TRAIL induces granulocyte apoptosis (3).
Effect of TRAIL on in vitro granulocyte migration. We asked whether the 
presence of TRAIL modulates granulocyte motility and chemotaxis. 
In an in vitro transmigration assay, PCW-activated granulocytes 
from bone marrow (BM) aspirates migrated along a leukotriene B4 
gradient. The number of granulocytes present in the target com-
partment after 1 hour was not influenced by the TRAIL genotype of 
the cells or by preincubation with rTRAIL (data not shown).
Immunocytochemical analysis of TRAIL expression in meningitis. We 
aimed to identify the sources of TRAIL expression in experimen-
tal meningitis. Using immunocytochemistry, we observed TRAIL 
immunoreactivity on granulocytes and monocytes in the CSF of 
wild-type mice at 12 hours after meningitis induction (Supple-
mental Figure 3B). As expected, no TRAIL immunoreactivity was 
detected in TRAIL–/– mice with meningitis (data not shown). The 
majority of MPO-immunoreactive granulocytes in the tissue did 
not show staining by the anti-TRAIL antibody (data not shown).
Experiments in BM chimeric mice. Four groups of BM chimeric 
mice were generated by the transplantation of lethally irradiated 
wild-type or TRAIL–/– mice with BM harvested from wild-type or 
TRAIL–/– mice (donor to recipient: TRAIL–/– to TRAIL–/–; TRAIL+/+ 
to TRAIL+/+; TRAIL–/– to TRAIL+/+; and TRAIL+/+ to TRAIL–/–). Fol-
lowing in vitro transduction of hematopoietic cells with a murine 
stem cell virus–based retrovirus encoding the enhanced GFP, 
peripheral blood was analyzed for enhanced GFP expression 5 
weeks after BM transplantation in order to determine the degree of 
chimerism (Figure 5A). Animals with less than 30% chimerism were 
excluded from the study. In the remaining animals, reconstitution 
of hematopoiesis with enhanced GFP–expressing peripheral blood 
cell progeny was on average 54% ± 13% with no significant differ-
ences among the groups (Figure 5B). At 24 hours after meningitis 
induction, TRAIL–/– mice reconstituted with TRAIL–/– BM cells had 
significantly more CSF pleocytosis than wild-type mice reconstitut-
ed with wild-type BM cells (Figure 5B). However, transplantation 
of TRAIL–/– BM cells into wild-type mice (TRAIL–/– to TRAIL+/+) 
increased CSF leukocyte counts at 24 hours to levels comparable to 
those of TRAIL–/–-to-TRAIL–/– mice and significantly higher than 
those of TRAIL–/–-to-TRAIL–/– mice. In contrast, transplantation of 
wild-type BM cells into TRAIL–/– mice (TRAIL+/+ to TRAIL–/–) result-
ed in low CSF leukocyte counts that were not different from those 
of TRAIL+/+-to-TRAIL+/+ mice but were significantly lower than 
those of TRAIL–/–-to-TRAIL–/– mice. Following extraction of total 
RNA from brain slices of BM chimeric mice at 24 hours after men-
ingitis induction, RT-PCR analysis revealed the presence of TRAIL 
mRNA in TRAIL+/+-to-TRAIL+/+ and in TRAIL+/+-to-TRAIL–/– mice 
but not in TRAIL–/–-to-TRAIL–/– mice (Figure 5C). These experi-
ments provide evidence that leukocytes are the primary source of 
TRAIL in meningitis and suggest an autocrine regulatory effect of 
leukocyte-derived TRAIL in acute CNS inflammation.
Findings in meningitis induced by live Streptococcus pneumoniae. Final-
ly, we aimed to determine whether regulatory effects of the TRAIL 
system were also present in meningitis induced by live bacteria. 
In wild-type mice infected with the D39 strain of S. pneumoniae, 
bacterial concentrations in the CSF after 24 hours were not influ-
Figure 5
Myeloid cells are the source of TRAIL in experimental meningitis. (A) In BM chimeric mice, the degree of chimerism was assessed by FACS 
analysis of peripheral blood leukocytes. Histogram plot demonstrates strong enhanced GFP expression in leukocyte populations from a chimera 
compared with that in leukocytes from a nontransplanted mouse. (B) The degree of CSF inflammation at 24 hours after meningitis induction in 
BM chimeric mice is determined by the genotype of the BM donor. Note that the levels of chimerism were comparable among all 4 groups of 
chimeras. CSF pleocytosis correlated negatively with TRAIL deficiency in hematopoietic cells. (C) Real-time PCR revealed presence of TRAIL 
mRNA in wild-type and TRAIL–/– mice transplanted with wild-type BM (C57/C57 and TRAIL–/–/C57, respectively) but absence of TRAIL mRNA 
expression in TRAIL–/– mice transplanted with TRAIL–/– BM (TRAIL–/–/TRAIL–/–). bps, base pairs.
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enced by intrathecal administration of 1 μg rTRAIL at the time 
of meningitis induction (Figure 6A). Leukocyte concentrations in 
the CSF at the end of the experiment (Figure 6B) and mortality of 
meningitis (Figure 6C) were significantly lower in rTRAIL-treated 
mice than in untreated mice with meningitis. Moreover, treatment 
with rTRAIL reduced the number of TUNEL-positive cells in the 
dentate gyrus at 24 hours after infection (Figure 6D).
Discussion
Deficiency in TRAIL protracted acute inflammation and increased 
apoptosis in the hippocampus in experimental meningitis. These 
deleterious changes were reversed by rTRAIL or by the transplanta-
tion of TRAIL-expressing BM cells into a chimeric mouse model. 
Administration of rTRAIL into the subarachnoid space of wild-
type mice with meningitis also reduced inflammation and apop-
tosis. We therefore identify TRAIL as a novel antiinflammatory 
cytokine in meningitis. Interestingly, increased concentrations of 
sTRAIL were found in patients with proven bacterial meningitis.
A major finding of our study is that TRAIL modifies the inflam-
matory response during experimental meningitis by regulating the 
recruitment and the survival of leukocytes. Previous ex vivo stud-
ies have also provided evidence for a role of TRAIL in the regula-
tion of leukocyte survival. Human neutrophils express the death 
domain–containing receptor, TRAIL-R2 and membrane-bound 
TRAIL, which is released in soluble form by unknown proteases 
(14). We confirmed the presence of TRAIL-R2 on murine granulo-
cytes. TRAIL and TRAIL death receptors promote apoptotic death 
of senescent circulating neutrophils upon their return to the BM 
(13). Activated tissue neutrophils have an extended life span due to 
the action of external survival signals such as GM-CSF, complement 
C5a, LPS, and type 1 interferons (36, 37) as well as temporary resis-
tance to CD95 signaling (38). In vitro, initiation of apoptosis was 
reported to be regulated by TNF-α through increased shedding of 
membrane-bound TRAIL and gradual downregulation of the decoy 
receptor TRAIL-R3 thereby promoting death signaling via TRAIL-
R2 (14). This is consistent with our findings of prolonged survival 
of activated CSF leukocytes in TRAIL–/– mice during meningitis and 
the increase of sTRAIL in the CSF of patients suffering from men-
ingitis. A further observation of our study was the delayed onset 
of meningeal inflammation in TRAIL–/– mice. The recruitment of 
neutrophils — otherwise the first line of defense in bacterial men-
ingitis — was affected most prominently by the absence of TRAIL. 
There are conflicting reports with regard to the modulatory effects 
of TRAIL on the activation of endothelial cells during inflamma-
tion and the subsequent immigration of leukocytes. One study 
reported induction of apoptosis and NF-κB–dependent inflam-
matory gene expression by TRAIL (39). A further study described 
markedly decreased production of the chemokines CCL8/mono-
cyte chemoattractant protein-2 (MCP-2) and CXCL10/IP-10, lead-
ing to a loss of the proadhesive activity of TNF-α in the presence of 
TRAIL (40). TRAIL could also exert a regulatory function on leuko-
cyte activation, e.g., expression of adhesion molecules, motility, or 
chemotaxis. Inhibitory effects of TRAIL on the activation of auto-
antigen-specific T cells have recently been described (8). However, 
we did not detect a direct effect of rTRAIL on CD18 expression on 
peripheral blood granulocytes. CD18 is considered to be a marker 
of activation and adhesiveness. Also, neither the TRAIL genotype 
nor the addition of rTRAIL had an influence on granulocyte motil-
ity along a leukotriene B4 gradient in cell migration experiments. 
Thus, the exact mechanisms of action leading to different leuko-
cyte kinetics in the presence and absence of TRAIL remain unclear 
at this time. However, based on the results obtained with BM chi-
meric mice, we conclude that the regulatory effect of TRAIL on the 
duration of the inflammatory process is mediated primarily within 
the leukocyte population. Leukocytes are both the relevant source 
and target of TRAIL since the inflammatory phenotype in the CSF 
and the detection of TRAIL mRNA in brains with meningitis were 
influenced by the genotype of the donor but not of the recipient 
mice. In patients with meningitis, the concentration of sTRAIL 
correlated with the number of leukocytes in the CSF. A contribu-
tion of BM-derived microglia as a source of TRAIL in the brains of 
chimeric mice appears unlikely as TRAIL is not normally found in 
brain tissue (41), and due to the rather short interval between BM 
transplantation and the induction of meningitis, only a very small 
number of these cells could be expected to derive from the trans-
planted hematopoietic cells (42).
Another important finding of our study is that TRAIL not only 
modifies the inflammatory response, but also determines the 
degree of brain damage in experimental meningitis. In the case of 
S. pneumoniae, the most frequent and invasive pathogen in bacte-
Figure 6
Effects of treatment with rTRAIL in meningitis induced by live pneu-
mococci. (A) At 24 hours after infection, bacterial load in the CSF in 
untreated and rTRAIL-treated wild-type mice did not differ. (B) CSF 
leukocyte concentration was significantly lower in rTRAIL-treated 
mice than in controls at 24 hours after infection with live pneumococci. 
**P < 0.01, Student’s t test. (C) During the experimental period of 24 
hours, mortality was higher in untreated versus rTRAIL-treated mice 
with meningitis. **P < 0.01, log rank test. (D) Apoptosis in the dentate 
gyrus at 24 hours after meningitis induction was reduced by treatment 
with 1 μg rTRAIL. **P < 0.01, Student’s t test.
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rial meningitis, neuronal injury is driven by bacterial toxins and 
by the inflammatory host response (25–27,43). On the host side, 
release of free radicals, proteases, and neurotoxic cytokines by 
immune cells contributes to the damage (32, 44). TNF-α caused 
hippocampal neurodegeneration in an infant rat model of men-
ingitis (45, 46), but no conclusive data are available on the role 
of CD95 and TRAIL systems. TRAIL receptors but not TRAIL are 
expressed in the healthy brain (41). The addition of high concen-
trations of TRAIL to human living brain slices increases neuronal 
apoptosis (47). Moreover, TRAIL has been identified as a mediator 
of neuronal cell death in experimental autoimmune encephalo-
myelitis (48). Thus, TRAIL released by immune-competent cells 
may confer death signals to neurons during inflammation. How-
ever, our findings of increased apoptosis in the hippocampus of 
TRAIL–/– mice with meningitis and of reduced apoptosis in wild-
type mice treated with rTRAIL during meningitis argue against a 
prominent direct contribution of TRAIL signaling to neuronal cell 
death during acute meningitis. On the contrary, TRAIL may limit 
host-induced cytotoxicity by supporting the resolution of inflam-
mation through enhanced apoptotic clearance of leukocytes. The 
importance of leukocytes as effectors of host-driven neurotoxicity 
is supported by our observation of reduced apoptosis in the hippo-
campus following blockade of leukocyte recruitment with a mono-
clonal antibody against CD18 or following granulocyte depletion 
in nonreplicative PCW-induced meningitis. These findings are in 
line with previously published data in other models of meningitis 
(15–17, 25, 46, 49). However, our histological findings suggest an 
indirect role of invading leukocytes, since MPO-positive granulo-
cytes were not found in the vicinity of apoptotic cells in the brain 
in untreated meningitis. Moreover, the reduction of meningitis-
induced apoptosis in the dentate gyrus of granulocyte-depleted 
mice was clearly independent of TRAIL. An additional protective 
mechanism of TRAIL besides enhanced leukocyte clearance may 
be the modulation of local inflammation within the brain paren-
chyma, as suggested by the elevated levels of cytokine gene expres-
sion in TRAIL–/– mice with meningitis. Along these lines, we and 
others (50) detected expression of TRAIL-R2 on CNS microglia.
In conclusion, we describe a new role for TRAIL as a modulator 
of granulocyte-driven inflammation. TRAIL limits the life span 
of activated leukocytes by its proapoptotic abilities. Furthermore, 
TRAIL appears to enhance granulocyte recruitment by as yet 
unknown mechanisms. The TRAIL pathway may therefore carry 
significant therapeutic potential for terminating an acute inflam-
matory response and improve the outcome of invasive infections.
Methods
Measurement of TRAIL in human CSF. Stored supernatants (–80°C) of CSF 
from 11 patients with acute bacterial meningitis were included in the 
analysis. Patients were recruited for study according to their diagnosis 
at discharge and had to meet the following criteria: (a) clinical syndrome 
consistent with bacterial meningitis; and (b) presence of more than 1000 
leukocytes/μl or cultural identification of the pathogen (S. pneumoniae, 
n = 5; Enterococcus faecalis, n = 1; Neisseria meningitidis, n = 2; unknown, n = 3). For 
controls, we included 11 patients in whom CSF analysis had revealed normal 
results (35). Patients had given informed consent to the lumbar puncture, 
and use of the samples in studies was approved by Ethikkommission der 
Charité — Universitätsmedizin Berlin. TRAIL concentrations in the CSF were 
measured in duplicate in a blinded fashion, using a specific ELISA for TRAIL 
according to the manufacturer’s protocol (R&D Systems). A control serum 
sample was applied consistently to exclude plate-to-plate variations.
Bacterial culture and preparation of PCWs. In experiments involving live 
bacteria, an encapsulated strain of S. pneumoniae serotype 2 (strain D39, 
originally derived from a clinical isolate) was used, while PCWs were pre-
pared from nonencapsulated pneumococci (strain R6). Bacteria were 
grown overnight in standard casein plus yeast medium at 37°C with 5% 
CO2. To prepare viable inocula, bacteria were pelleted during log phase 
growth and resuspended in pyrogen-free PBS. CFUs/μl were determined 
photometrically (optical extinction at 620 nm) using a standard curve, and 
serial dilutions were used to prepare defined inocula of 106 CFUs/animal 
in volumes of 40 μl. Correctness of the CFU calculations was verified by 
plating of serial dilutions.
Purified PCW was prepared as described (15, 51). Following heat inactiva-
tion, bacteria were mechanically disintegrated. The suspension was digest-
ed with 10 μg/ml DNase (Promega) and 50 μg/ml RNase (USB Corp.) for 
1 hour at 37°C followed by treatment with 0.01% trypsin (Sigma-Aldrich) 
for 2 hours at 37°C. The digest was sedimented by centrifugation (23,000 g, 
20 min) and resuspended in 2% SDS (SERVA) at 90°C for 20 minutes fol-
lowed by 8 cycles of washing. Using a standard curve, the optical density of 
the solution was adjusted to correspond to a concentration of 107 CFUs/40 
μl. The chemical composition of this cell wall has been published (52).
Animal experiments. Studies were conducted in a well-characterized model 
of nonreplicative pneumococcal meningitis (35). Animal care, use for 
experiments, and all experimental protocols were reviewed and approved by 
Landesamt für Gesundheit und Soziales, Berlin, Germany. Meningitis was 
induced in 8- to 12-week-old male C57BL/6 mice or TRAIL–/– mice (back-
crossed for more than 8 generations to the C57BL/6 background; ref. 45) 
by instillation of 40 μl PCW preparation equivalent to 107 CFUs into the 
lumbar spinal canal as described (35). Controls received an equal volume of 
pyrogen-free PBS. Adequate awakening from the anesthesia and absence of 
pareses were verified clinically. A subset of animals was treated with rTRAIL 
(45), which was injected intrathecally at the time of meningitis induction. 
To minimize potential contamination with LPS, a commercially available 
LPS removal kit (End-X Endotoxin Affinity Resin; Associates of Cape Cod) 
was used according to the manufacturer’s instructions. In some animals, 
leukocyte recruitment was blocked by injection of a monoclonal antibody 
directed against CD18 (clone GAME46; BD Biosciences — Pharmingen). The 
antibody was injected into the tail vein at a concentration of 1 mg/kg at the 
time of meningitis induction, followed by repeated intraperitoneal injections 
of 0.1 mg/kg antibody after 6, 12, and 18 hours. Additional experiments were 
conducted in granulocyte-depleted mice. For this purpose, TRAIL–/– mice 
(n = 10) received a single intraperitoneal injection of a monoclonal rat anti-
Ly6G antibody (BD Biosciences — Pharmingen; 0.1 mg/animal) at 24 hours 
prior to surgery. Efficiency of this procedure was verified by hematological 
examination of peripheral blood for the presence of less than 1% granulo-
cytes at the time of meningitis induction. TRAIL–/– mice (n = 10) injected 
with nonspecific rat IgG (BD Biosciences — Pharmingen; 0.1 mg/animal) 
were used as nondepleted controls.
At the end of the experiments, animals were examined using the tightrope 
test (53). In this global motor and coordination task, the length of time 
during which a mouse is able to hold on to a horizontally suspended length 
of string is measured. Mice are lifted by the tail and released once they have 
firmly gripped the rope with both forepaws. A padded box is used to catch 
falling mice. The experiment was terminated after 30 seconds. Following 
this test, the animals were again deeply anesthetized. After dissection of the 
occipital muscles under a preparation microscope, a CSF sample was drawn 
from the cisterna magna using a 28G butterfly cannula attached to a micro-
liter syringe. Obtained CSF samples ranged between 10 and 20 μl/mouse. 
Leukocytes in the CSF were counted using a Fuchs-Rosenthal chamber at 
400-fold magnification. Following transcardial perfusion with cold PBS, 
brains were harvested and snap frozen using methylbutane and dry ice.
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Generation of BM chimeric mice. Chimeras were generated as described (48, 54). 
In brief, BM cells from 8- to 12-week-old male donor mice pretreated 
with 5-fluorouracil were stimulated with 20 ng/ml IL-3, 50 ng/ml IL-6, 
and 50 ng/ml SCF (PromoCell) for 48 hours. In order to facilitate the 
assessment of chimerism, donor BM cells were genetically modified with 
a murine stem cell virus–based (MSCV-based) retroviral vector encoding 
the enhanced GFP. BM cells were cocultured with irradiated (1,300 cGy) 
GP+E86 viral producer cells. After another 48 hours, BM cells were recov-
ered from the cultures, and 5 × 106 nonadherent BM cells were trans-
planted by tail vein injection into lethally irradiated (2 doses of 550 cGy 
separated by 3 hours) recipient mice. Five weeks after BM transplantation, 
peripheral blood was examined for enhanced GFP expression by FACS 
(FACSCalibur; BD). Dead cells (propidium iodide positive) were excluded. 
Data were evaluated using CellQuest software (version 3.1; BD). Only ani-
mals with more than 30% of chimerism were used for experiments.
CSF studies. Viability of CSF leukocytes was assessed by AOEB staining. 
AO and EB are fluorescent intercalating DNA dyes. While AO stains all 
nuclei green, EB is excluded by cells with an intact cell membrane. Double 
staining with EB and AO allows for differentiation of live, apoptotic, and 
necrotic cells (26): live cells have green, regular-sized nuclei. Nuclear con-
densation or fragmentation identifies apoptotic cells, and red staining 
identifies late apoptotic or necrotic cells. For AOEB staining, CSF samples 
were diluted 1:20 in 0.1% PBS in 96-well cell culture plates. AO and EB 
were added to a final concentration of 2 μg/ml each. In additional samples, 
TUNEL reaction was used to label DNA strand breaks, a hallmark of apop-
tosis. For this purpose, CSF samples were air dried and briefly fixed with 4% 
paraformaldehyde on coated glass slides. TUNEL reaction was performed 
using a commercially available kit (Qbiogene) according to the manufac-
turer’s instructions. A FITC conjugate was used for visualization. Hoechst 
33258 (1:10,000) was employed as a nuclear counterstain. To determine 
whether TRAIL abbreviates the lifespan of activated CSF leukocytes, CSF 
was obtained from TRAIL–/– mice 12 hours after intrathecal challenge. 
Due to the small volumes, samples were pooled and diluted 1:10 in RPMI 
medium. rTRAIL (100 ng/ml) was added to one half of the sample (4). Fol-
lowing incubation at 37°C for 0, 2.5, 5, and 8.5 hours, the percentage of 
dead cells was determined in the TRAIL-exposed and untreated sample 
using AOEB staining as above.
For immunocytochemical detection of TRAIL on CSF leukocytes, cells 
were fixed on to glass slides and incubated with an antibody against TRAIL 
(clone N2B2; eBioscience) at a dilution of 1:100 for 1 hour at ambient tem-
perature. A Texas red–conjugated anti-rat secondary antibody was used for 
visualization, and Hoechst 33258 was used as a nuclear counterstain. To 
control for nonspecific binding of the conjugate, additional slides were 
processed with omission of the primary antibody. CSF leukocytes from 
TRAIL–/– mice were used as a negative control.
Histology and immunohistochemistry. To determine the extent of apoptosis 
in the dentate gyrus, 20-μm cryosections were thaw-mounted on coated 
glass slides. Following fixation in –20°C methanol for 10 minutes, slides 
were processed for TUNEL reaction using a commercially available fluo-
rescent kit (Qbiogene). Slides were counterstained with Hoechst 33258 
(1:10,000). TUNEL-positive condensed or fragmented nuclei were counted 
in the dentate gyrus and hilus region of both hemispheres on multiple 
sections per animal in a blinded fashion. The area of the dentate gyrus 
was determined using Stereo Investigator software (version 5.05.4; MBF 
Bioscience). Apoptotic cells were then divided by the dentate gyrus area to 
allow interindividual comparisons. For immunohistochemistry, sections 
were treated with 3% normal goat serum and 0.3% Triton X-100 (Sigma-
Aldrich) at room temperature for 1 hour. Granulocytes were stained using 
a rabbit antibody against MPO (Chemicon) at a dilution of 1:300 at 4°C 
overnight. A monoclonal hamster anti-mouse antibody against TRAIL-R2 
(clone MD5-1; eBioscience) was used at a concentration of 1:100. Texas 
red–conjugated goat anti-hamster antibody (Vector Laboratories) and 
Alexa Fluor 488–conjugated goat anti-rabbit antibody (Invitrogen) were 
added at a concentration of 1:100 at room temperature for 1 hour to 
allow visualization of the staining. For double stainings, tissue was first 
processed for MPO immunohistochemistry using a Texas red conjugate 
followed by the TUNEL technique as described above.
RNA isolation and real-time PCR. Total RNA was extracted from cerebellar 
lysates using the TriFast method (peqGold TriFast; PEQLAB) following 
the manufacturer’s instructions. First-strand cDNA was synthesized in a 
volume of 20 μl using 1 μg of total RNA and TaqMan reverse transcription 
reagents (Applied Biosystems). The RNA was quantified at 260 nm in a 
NanoDrop spectrophotometer at an OD 260/280 ratio of 1.7 to 2.0 for 
all samples. PCR was performed with an ABI PRISM 7000 (Applied Bio-
systems) and 2 × qPCR MasterMix (Eurogentec) according to the manu-
facturers’ instructions. To quantify target mRNA levels, TGF-β, TNF-α, 
IFN-γ, IL-10, and IL-4 TaqMan Gene Expression assays were purchased 
from Applied Biosystems. The sequences CXCL12 (forward) 5′-CCAGAGC-
CAACGTCAAGCA-3′, CXCL12 (reverse) 5′-TGCACACTTGTCTGTTGTT-
GTTCTT-3′, and CXCL12 (probe) 5′-Fam-CTCAACACTCCAAACTGT-
GCCCTTCAGA-TAMRA-3′ were designed with Primer Express software 
(version 2.0; Applied Biosystems). All primers spanned an intron to ensure 
discrimination between cDNA and genomic DNA. The relative amount of 
specific mRNA was normalized to GAPDH using the following sequences: 
GAPDH (forward) 5′-CTCAACTACATGGTCTACATGTTCCA-3′; GAPDH 
(reverse) 5′-CCATTCTCGGCCTTGACTGT-3′; and GAPDH (probe) 5′-
Fam-TGACTCCACTCACGGCAAATTCAACGT-TAMRA-3′. All PCR reac-
tions were run in duplicate and were performed with 40 cycles, including 
a negative control consisting of PCR-grade water. Quantitative real-time 
PCR analysis was carried out using the 2-ΔΔCt method (55).
In vitro studies of murine blood. Differential hemograms were obtained 
microscopically in a Neubauer counting chamber after diluting peripheral 
blood samples in Turk’s solution (1:20). In order to differentiate leukocyte 
subpopulations in the CSF, samples were air dried on untreated glass slides 
and stained with May-Grünwald and Giemsa solutions. For each animal, 
200 leukocytes were assessed at 400-fold magnification.
Peripheral blood of naive C57BL/6 mice (n = 7) was collected in PBS with 
2 mM EDTA. For the detection of TRAIL-R2 on neutrophils, samples were 
subjected to erythrocyte lysis and incubated with anti-CD14/CD32 anti-
body (BD Biosciences — Pharmingen) at a concentration of 1:50 to prevent 
nonspecific binding. Granulocytes were identified by their high Gr-1 expres-
sion using a PE-labeled anti–Gr-1 monoclonal antibody (BD Biosciences — 
Pharmingen) at a dilution of 1:100 at 4°C for 25 minutes. The expression of 
TRAIL-R2 was analyzed by flow cytometry using a polyclonal goat antibody 
against TRAIL-R2 (ALEXIS Biochemicals) at a dilution of 1:200 at 4°C for 
30 minutes. Leukocytes not incubated with one or both primary antibodies 
served as controls. Samples were analyzed by 4-color flow cytometry on a 
FACSCalibur, and 8,000 gated granulocytes were measured.
To determine the effect of TRAIL on granulocyte activation, murine 
peripheral blood leukocytes were harvested as above and transferred to 
RPMI 1640 medium (Invitrogen). For stimulation, cells were incubated at 
37°C for 10 minutes with PCW (prepared as above, 1:20 dilution), rTRAIL, 
or both. As a positive control, 1 μM PMA (Sigma-Aldrich) was used for 
maximum stimulation. After washing the cells, samples were incubated 
for 30 minutes with APC-labeled anti–Gr-1, PE-labeled anti-CD11b, and 
FITC-labeled anti-CD18 antibodies (BD Biosciences — Pharmingen) at a 
dilution of 1:20. After washing, cells were analyzed on a FACSCalibur. 
CD11bhigh/Gr-1high granulocytes were gated and analyzed for the expres-
sion of CD18 as a marker of activation. CellQuest software (version 3.1; 
BD) was used for quantification.
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To study the effect of TRAIL on migratory capacity, BM cells were 
obtained from femurs and tibiae of wild-type and TRAIL–/– mice by flushing 
with RPMI supplemented with 10% FBS. Erythrocytes were depleted using 
ammonium chloride. BM cells were activated by incubation with PCW 
(1:20 dilution) for 12 hours at 37°C with or without addition of 1 μg/ml 
rTRAIL. We added 200 μl of cell suspension, equivalent to 200,000 cells, to 
transwell polycarbonate inserts (5-μm pore size; Costar) and placed these 
inserts into 24-well plates containing 600 μl/well of RPMI with 10% FBS 
and 100 nM leukotriene B4 (Cayman Chemical). Cells were then allowed 
to migrate at 37°C for 1 hour. At the end of the experiment, granulocytes 
in the lower compartment were quantified using flow cytometry by study 
of the expression of the granulocyte marker Gr-1 as above.
Statistics. For 2-group comparisons, Student’s t test was used in the pres-
ence of normal distribution (Kolmogorov-Smirnov test); otherwise, Mann-
Whitney U test was used. ANOVA was consistently used for multigroup com-
parisons. To compare groups with equal variance, 1-way ANOVA was used 
followed by Student-Neuman-Keuls post hoc analysis. In samples failing 
equal variance testing, Kruskal-Wallis ANOVA on ranks was used followed 
by Dunn’s post hoc analysis. Two-way ANOVA was used to test for an inde-
pendent effect of rTRAIL on neuronal apoptosis in the granulocyte-depleted 
mice. Spearman’s r was used to describe the correlation between leukocyte 
count and sTRAIL concentration in patients. Multiple regression analysis 
was used to determine the relative impact of genotype and CSF leukocyte 
count on the number of apoptotic cells in the dentate gyrus. We performed 
log rank tests to compare survival between untreated and rTRAIL-treated 
mice with meningitis induced by live pneumococci and to test differences 
between groups in the motor coordination task (tightrope test).
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